These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 35367668

  • 1. Fibroblast growth factor 19 stimulates water intake.
    Ursic-Bedoya J, Chavey C, Desandré G, Meunier L, Dupuy AM, Gonzalez-Dopeso Reyes I, Tordjmann T, Assénat E, Hibner U, Gregoire D.
    Mol Metab; 2022 Jun; 60():101483. PubMed ID: 35367668
    [Abstract] [Full Text] [Related]

  • 2. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J, Du F, Dang Y, Li X, Qian M, Feng W, Qiao C, Fan D, Nie Y, Wu K, Xia L.
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [Abstract] [Full Text] [Related]

  • 3. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y.
    J Exp Clin Cancer Res; 2017 Jan 09; 36(1):8. PubMed ID: 28069043
    [Abstract] [Full Text] [Related]

  • 4. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D, Miyazaki M.
    BMC Cancer; 2012 Feb 06; 12():56. PubMed ID: 22309595
    [Abstract] [Full Text] [Related]

  • 5. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
    Lin ZZ, Hsu C, Jeng YM, Hu FC, Pan HW, Wu YM, Hsu HC, Hu MC, Cheng AL.
    Liver Int; 2019 Sep 06; 39(9):1682-1691. PubMed ID: 30698907
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y, Zhang W, Doughtie A, Cui G, Li X, Pandit H, Yang Y, Li S, Martin R.
    Oncotarget; 2016 Aug 09; 7(32):52329-52339. PubMed ID: 27447573
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
    Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L, Teng Y.
    Oncotarget; 2016 Mar 22; 7(12):13575-86. PubMed ID: 26498355
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1.
    Guo C, Zhou N, Lu Y, Mu M, Li Z, Zhang X, Tu L, Du J, Li X, Huang D, Xu Q, Zheng X.
    Biomed Pharmacother; 2024 Jan 22; 170():115955. PubMed ID: 38048735
    [Abstract] [Full Text] [Related]

  • 15. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
    Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y.
    PLoS One; 2012 Jan 22; 7(3):e33870. PubMed ID: 22442730
    [Abstract] [Full Text] [Related]

  • 16. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
    Tao Z, Cui Y, Xu X, Han T.
    Proc Natl Acad Sci U S A; 2022 Oct 04; 119(40):e2208844119. PubMed ID: 36179047
    [Abstract] [Full Text] [Related]

  • 17. FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis.
    Ursic-Bedoya J, Desandré G, Chavey C, Marie P, Polizzi A, Rivière B, Guillou H, Assenat E, Hibner U, Gregoire D.
    EMBO Mol Med; 2024 Feb 04; 16(2):238-250. PubMed ID: 38228803
    [Abstract] [Full Text] [Related]

  • 18. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
    Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N.
    Sci Rep; 2021 Mar 05; 11(1):5303. PubMed ID: 33674622
    [Abstract] [Full Text] [Related]

  • 19. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR.
    Liver Int; 2014 Jul 05; 34(6):e1-9. PubMed ID: 24393342
    [Abstract] [Full Text] [Related]

  • 20. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
    Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T, Learned RM, DePaoli AM, Tian H, Ling L.
    Cancer Res; 2014 Jun 15; 74(12):3306-16. PubMed ID: 24728076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.